Literature DB >> 1701471

Competitive ELISA for the measurement of tau protein in Alzheimer's disease.

C R Harrington1, P C Edwards, C M Wischik.   

Abstract

Tau protein is a major component of paired helical filaments (PHFs) which constitute the characteristic neurofibrillary tangle lesions observed in Alzheimer's disease. Two tau mAbs have been produced which show distinct patterns of immunoreactivity with intact human tau and with tau incorporated in PHFs. The mAb 423 recognises PHFs but not human tau on immunoblots whereas mAb 7/51 reacts with human tau but its epitope is buried within the PHF and is only exposed after formic acid treatment. A competitive ELISA has been developed for both of these mAbs and these have been used to quantify the two distinct tau epitopes in PHFs. Samples containing antigen are incubated with horseradish peroxidase-conjugated mAb at 4 degrees C for 16 h and non-adsorbed antibody then measured by binding, at 37 degrees C for 1 h, to a fragment of tau coated on microtitre plates. Bound enzyme-labelled antibody is measured kinetically using a spectrophotometer capable of automatically mixing the samples throughout a 2-min incubation with substrate and chromogen. The interfacing of the plate reader with a computer permits competitive curves to be plotted automatically using Softmax. Curves are fitted using a 4-parameter logistic algorithm which allows one to determine the relative immunoreactivity for different samples. The application of these assays to monitoring biochemical fractions and quantifying distinct immunochemical presentations of tau protein with these two mAbs is described.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701471     DOI: 10.1016/0022-1759(90)90388-c

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease.

Authors:  C R Harrington; E B Mukaetova-Ladinska; R Hills; P C Edwards; E Montejo de Garcini; M Novak; C M Wischik
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

2.  Biochemical and anatomical redistribution of tau protein in Alzheimer's disease.

Authors:  E B Mukaetova-Ladinska; C R Harrington; M Roth; C M Wischik
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

3.  Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51.

Authors:  M Novak; R Jakes; P C Edwards; C Milstein; C M Wischik
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

4.  Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Authors:  C M Wischik; P C Edwards; R Y Lai; M Roth; C R Harrington
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

5.  Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease.

Authors:  Robert Y K Lai; Charles R Harrington; Claude M Wischik
Journal:  Biomolecules       Date:  2016-04-08

6.  Identification of 3- and 4-repeat tau isoforms within the PHF in Alzheimer's disease.

Authors:  R Jakes; M Novak; M Davison; C M Wischik
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

7.  Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia.

Authors:  Nora Lemke; Valeria Melis; Dilyara Lauer; Mandy Magbagbeolu; Boris Neumann; Charles R Harrington; Gernot Riedel; Claude M Wischik; Franz Theuring; Karima Schwab
Journal:  J Biol Chem       Date:  2020-10-30       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.